Bosco, D, Plastino, M, Colica, C, Bosco, F, Arianna, S, Vecchio, A, Galati, F, Cristiano, D, Consoli, A, Consoli, D. Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease. Clin Neuropharmacol 2012; 35(3): 118–120.CrossRefGoogle Scholar

Papay, K, Xie, SX, Stern, M, Hurtig, H, Siderowf, A, Duda, JE, Minger, J, Weintraub, D. Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology 2014; 83(9): 826–833.CrossRefGoogle Scholar

AHFS Drug information, 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 30 December 2022 via www.medicinescomplete.com.Google Scholar

Dannon, PN, Lowengrub, K, Musin, E, Gonopolsky, Y, Kotler, M. 12-Month follow-up study of drug treatment in pathological gamblers: a primary outcome study. J Clin Psychopharmacol 2007; 27(6): 620–624.CrossRefGoogle ScholarPubMed

Grant, JE, Kim, SW. A case of kleptomania and compulsive sexual behavior treated with naltrexone. Ann Clin Psychiatry 2001; 13(4): 229–231.CrossRefGoogle ScholarPubMed

Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed on 30 December 2022 via www.medicinescomplete.com.Google Scholar

Kim, SW, Grant, JE, Adson, DE, Shin, YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 2001; 49(11): 914–921.CrossRefGoogle Scholar

Naltrexone. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 30 December 2022 via www.medicinescomplete.com.Google Scholar

Naltrexone. In: DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Accessed on 30 December 2022 via www.micromedexsolutions.com.Google Scholar

Neumeister, A, Winkler, A, Wöber-Bingöl, C. Addition of naltrexone to fluoxetine in the treatment of binge eating disorder. Am J Psychiatry 1999; 156(5): 797.CrossRefGoogle ScholarPubMed

Rascol, O, Fabre, N, Blin, O, Poulik, J, Sabatini, U, Senard, JM, Ané, M, Montastruc, JL, Rascol, A. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson’s disease. Mov Disord 1994; 9(4): 437–440.CrossRefGoogle Scholar

Summary of Product Characteristics – Adepend 50 mg film coated tablets. AOP Orphan Ltd. Electronic Medicines Compendium: Adepend 50 mg film coated tablets – summary of product characteristics (SmPC) – (emc). Accessed on 30 December 2022 via www.medicines.org.uk.Google Scholar

Verebey, K, Volavka, J, Mulé, SJ, Resnick, RB. Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther 1976; 20(3): 315–328.CrossRefGoogle ScholarPubMed